Insulin Aspart Pen NovoLog FlexPen

Insulin, Biosimilar and FDA

FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like i

Northeast Mississippi Daily Jour… · 18h

FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can increase patient access to safe and effective treatment options.

Seeking Alpha on MSN · 16h

Sanofi gets FDA approval for NovoLog insulin biosimilar

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus.

Business Insider · 17h

FDA approves Sanofi biosimilar product for treatment of diabetes

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric

Medscape1y

Patient Satisfaction and Costs Associated With Insulin Administered by Pen Device or Syringe During Hospitalization

Patients received the FlexPen if they were randomized to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin aspart) or the combination of 70% ...

Hosted on MSN2mon

Novo Nordisk slashes U.S. list prices for insulin meds Tresiba, Fiasp

and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same price as NovoLog (insuin aspart), while Tresiba's price will be ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Insulin, Biosimilar and FDA

Trending now